Skip to main content
Equibles
KALA logo

KALA · KALA BIO, Inc.

Track KALA — free

Use KALA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KALA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.39 -0.03 (-8.20%) At close · Oct 2
Rebalance outlook locked
Market Cap
$9.20M
Shares
19.34M
Volume · Oct 2 1.08M Avg daily vol (3M) 1.43M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.39 Open$0.41 Day$0.38–0.42 52W close$0.39–82.00 Avg vol 30d2.9M Short int445K · 2.3% float · 1.0d Short vol56% Last earningsAug 8, 2025 DataJan 2020–Oct 2026 Filing10-Q · Aug 19

Up next

Latest filing: 10-Q
filed Aug 19, 2026
Q2 2022 earnings call transcript
call held Aug 11, 2022

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.3%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −96%
below
Price vs 50-day avg −42%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −31%
trailing
6-month return −97%
trailing
YTD return −99%
this year
Relative strength −109%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $10 — 200d above 50d
Institutional flow Distributing
-50% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.30% of float · ▲ +10.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
15 holders — near 3-yr low, contrarian setup
Squeeze score 38
low risk · 0–100
Fundamentals
Strong
EPS growth +67%
Y/Y
Free cash flow $-33.3M
Balance sheet $20.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 134%
annualized · 1-yr
Max drawdown −100%
past year
ATR 20.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−96% Bearish
Price vs 50-day avg
−42% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $10 — 200d above 50d
Institutional flow Distributing
-50% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.30% of float · ▲ +10.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
15 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $82
vs 200-day avg -96% vs 50-day avg -42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KALA
KALA BIO, Inc.
this stock
$9.20M — — — 2.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
15
% held
3.6%
Net QoQ
+667.2K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Rising
Shares short
445.4K
Days to cover
1.0d
Change
+42.3K sh
View
Short Volume
Short vol %
56%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
15.5K
Value
$8.7K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
64.9%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-27.0M
EPS diluted
$-165.50
View
Filings
SEC Filings
Latest
DEF 14A
Filed
Sep 24, 2026
This year
17
View
Proposed Sales
Value
$3.8K
Shares
14.5K
Filed
Mar 17, 2026
View
Exempt Offerings
Offering
$1.8M
Filed
Mar 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Aug 8, 2025
View

Performance

5D 20D 120D MTD YTD
KALA -19.1% -31.4% -96.6% -10.3% -98.6%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -18.8% -30.9% -108.7% -11.2% -111.5%
Key facts CIK 1479419 CUSIP 483119301 13F (30d) 1 filings 1 filers Visit website Investor relations